EGFR and breast cancer: In head and neck and esophageal squamous cell carcinomas, AXL dimerizes with EGFR and activates PKC through PLCγ [76], and in breast cancer pharmacological inhibition, PKC resulted in decreased AXL expression [62], suggesting a feedback loop between AXL expression and PKC activation.